信达生物玛仕度肽注射液启动III期临床适应症为高血压合并超重/肥胖人群的血压控制

新浪财经02-28

药物临床试验登记与信息公示平台数据显示，信达生物制药（苏州）有限公司的玛仕度肽注射液一项在未接受降压药治疗的轻、中度高血压合并超重/肥胖的参与者中评估IBI362有效性和安全性的多中心、随机、双盲、安慰剂对照临床研究已启动。临床试验登记号为CTR20260680，首次公示信息日期为2026年02月28日。该药物剂型为注射液，用法用量为按照临床方案给药，用药时程为按照临床方案给药。本次试验主要目的为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2614148888?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-28 18:03","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2614148888","market":"hk","top_or_hot":-1,"title":"信达生物玛仕度肽注射液启动III期临床 适应症为高血压合并超重/肥胖人群的血压控制","media":"新浪财经","content":"<div>\n<p>药物临床试验登记与信息公示平台数据显示，信达生物制药（苏州）有限公司的玛仕度肽注射液一项在未接受降压药治疗的轻、中度高血压合并超重/肥胖的参与者中评估IBI362有效性和安全性的多中心、随机、双盲、安慰剂对照临床研究已启动。临床试验登记号为CTR20260680，首次公示信息日期为2026年02月28日。该药物剂型为注射液，用法用量为按照临床方案给药，用药时程为按照临床方案给药。本次试验主要目的为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228185958a72a562d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>信达生物玛仕度肽注射液启动III期临床 适应症为高血压合并超重/肥胖人群的血压控制</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n信达生物玛仕度肽注射液启动III期临床 适应症为高血压合并超重/肥胖人群的血压控制\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-28 18:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228185958a72a562d&s=b><strong>新浪财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>药物临床试验登记与信息公示平台数据显示，信达生物制药（苏州）有限公司的玛仕度肽注射液一项在未接受降压药治疗的轻、中度高血压合并超重/肥胖的参与者中评估IBI362有效性和安全性的多中心、随机、双盲、安慰剂对照临床研究已启动。临床试验登记号为CTR20260680，首次公示信息日期为2026年02月28日。该药物剂型为注射液，用法用量为按照临床方案给药，用药时程为按照临床方案给药。本次试验主要目的为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228185958a72a562d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828557.USD","symbol_name":"AZ EQUITY CHINA \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228185958a72a562d&s=b","article_id":"2614148888","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228185958a72a562d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614148888","pubTimestamp":1772272980,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"药物临床试验登记与信息公示平台数据显示，信达生物制药（苏州）有限公司的玛仕度肽注射液一项在未接受降压药治疗的轻、中度高血压合并超重/肥胖的参与者中评估IBI362有效性和安全性的多中心、随机、双盲、安慰剂对照临床研究已启动。玛仕度肽注射液为化学药物，适应症为高血压合并超重/肥胖人群的血压控制。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","BK1583":"高瓴概念","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1589":"北水核心资产","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK1161":"生物科技","01801":"信达生物","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A"},"translate_title":"Innovent Biologics Masdopeptide Injection initiates phase III clinical indication for blood pressure control in hypertensive and overweight/obese people","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1.5},"content_text":"药物临床试验登记与信息公示平台数据显示，信达生物制药（苏州）有限公司的玛仕度肽注射液一项在未接受降压药治疗的轻、中度高血压合并超重/肥胖的参与者中评估IBI362有效性和安全性的多中心、随机、双盲、安慰剂对照临床研究已启动。临床试验登记号为CTR20260680，首次公示信息日期为2026年02月28日。该药物剂型为注射液，用法用量为按照临床方案给药，用药时程为按照临床方案给药。本次试验主要目的为治疗第16周，评估与安慰剂相比，IBI362对平均诊室坐位收缩压（Mean Sitting Systolic Arterial Pressure，msSBP）的影响。玛仕度肽注射液为化学药物，适应症为高血压合并超重/肥胖人群的血压控制。高血压合并超重/肥胖是常见的慢性疾病组合，超重/肥胖会增加高血压风险，患者常需综合管理血压与体重，诊断依赖血压测量和体重指数评估。本次试验主要终点指标包括第16周，给药间隔末期（谷浓度）msSBP较基线的变化；次要终点指标包括ABPM计算的SBP和DBP降压效应的谷/峰比值、ABPM监测的全监测期平均SBP等相对基线的变化、IBI362对msSBP等指标的影响、IBI362对降压有效率和达标率的影响、IBI362对动态血压监测指标的影响、IBI362对体重等代谢相关指标的影响、IBI362的安全性和耐受性、第24周msSBP较基线的变化、第16和24周体重较基线的百分比变化。目前，该试验状态为进行中（尚未招募），目标入组人数336人。声明：市场有风险，投资需谨慎。本文为AI大模型基于第三方数据库自动发布，不代表新浪财经观点，任何在本文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系biz@staff.sina.com.cn。责任编辑：小浪快报","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614148888","isCrawlerRequest":true}

信达生物玛仕度肽注射液启动III期临床 适应症为高血压合并超重/肥胖人群的血压控制

精彩评论

信达生物玛仕度肽注射液启动III期临床适应症为高血压合并超重/肥胖人群的血压控制